Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients

Everest Medicines announced that China’s National Medical Products Administration has approved Nefecon® for the treatment of primary immunoglobulin A nephropathy in adults at risk of disease progression.